glp 1 and heart rate The cardiovascular effects of GLP-1 receptor agonists beyond obesity type 2 diabetes: An anti-atherosclerotic action GLP-1 Agonists in Cardiovascular Diseases:

Not a supplement company

The FDA requires GLP-1 receptor agonists to carry a black-box warning regarding the risk of thyroid C-cell tumors, and it recommends against using them in patients with a personal or family history of medullary thyroid cell cancer or multiple endocrine neoplasia syndrome type 2a or 2b

The roles of motilin and ghrelin in gastrointestinal motility

The trial was small and short, and the participants were predominantly already taking metformin (some with a sulfonylurea) alongside diet and exercise, which makes it hard to isolate the probiotic's specific contribution

10.3389/fendo.2022.910256 78